Table 2.

Summary of in vivo local field potential (LFP) data

Drug class	Drug	Subst nigra	Amygd	Thalms	Nuc acmb	HC	mPFC	OFC	Mot cortx	Sens cortx
SSRIs	Acute escitalopram								↔Alpha, theta, gamma
	Acute citalopram									↓Gamma
	Acute fluvoxamine					↔Theta, gamma
SNRIs	Acute duloxetine								↔Theta, gamma, ↓alpha
TCAs	Acute desipramine					↑Theta, ↑gamma (trend)
MAOIs	Acute moclobemide					↓All freq		↓All freq
NDRIs	Chronic bupropion				↑Beta, delta, theta
Misc	Acute reboxetine					↑Theta, gamma
Novel	Acute vortioxetine								↑Theta, alpha, gamma
	Acute F15599						↔Delta
	Acute Zembrin					↓Alpha, beta, delta, theta
NMDAR antag	Acute MK-801		↑Delta, theta, ↔alpha, ↓beta, gamma	↑Delta, ↕theta, ↔alpha, ↓beta, gamma	↑hfo, ↕gamma, ↓delta	↑hfo, ↕gamma, theta, ↔delta, alpha, beta	↑hfo, ↑gamma, disrupts delta	↑Gamma		↑hfo, gamma
	Acute PCP					↔All freq	↓Delta
	Acute ketamine	↑hfo, gamma			↑hfo, gamma	↑hfo, ↕gamma, ↓theta, ↕delta, ↓alpha	↑Gamma, ↓theta	↓Unspecified freq		↑gamma, delta
	Chronic ketamine									↓gamma

Arrows indicate an increase (↑) in LFP power (averaged across all animals) in that frequency band, decrease (↓), or no change (↔), found in at least one study. Chronic includes 5 days or more; acute includes 1 and 2 day treatments as well as single injections. Table does not include drug interaction studies. Only includes wild type animals and systemically administered drugs. Only invasive, intracranial LFP recordings are shown, not skull surface recordings

Abbreviations (see Table 1 legend as well): Amygd amygdala, Thalms thalamus, Nuc acmb nucleus accumbens, Mot cortx motor cortex, Sens cortx sensory cortex